The use of CRISPR/Cas9 gene editing system in the treatment of HBV infection

Author :  

DOI : 10.29228/genediting.40389
Year-Number: 2020-1
Yayımlanma Tarihi: 2020-01-01 23:06:39.0
Language : English
Konu : Medical Genetics
Number of pages: 1-7  
Mendeley EndNote Alıntı Yap

Abstract

Hepatitis B disease is an infectious disease caused by the Hepatitis B virus (HBV) which may have different consequences such as cirrhosis and liver cancer. Although there is an effective vaccine against HBV, it is still a serious health problem for underdeveloped and some developing countries where the vaccination rate is low. Current treatments cannot clear all the viral infections. Therefore, there is an urgent need for definitive HBV treatment. The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) method is frequently used in vitro and in vivo for genetic modifications, including targeting the HBV genome. Therefore, in this review, the use of CRISPR/Cas9 technology in the HBV genome for treatment purposes will be discussed with the aid of recent literature

Keywords

Abstract

Hepatitis B disease is an infectious disease caused by the Hepatitis B virus (HBV) which may have different consequences such as cirrhosis and liver cancer. Although there is an effective vaccine against HBV, it is still a serious health problem for underdeveloped and some developing countries where the vaccination rate is low. Current treatments cannot clear all the viral infections. Therefore, there is an urgent need for definitive HBV treatment. The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) method is frequently used in vitro and in vivo for genetic modifications, including targeting the HBV genome. Therefore, in this review, the use of CRISPR/Cas9 technology in the HBV genome for treatment purposes will be discussed with the aid of recent literature

Keywords

Kaynakça

  • Aubert M, Ryu BY, Banks L, Rawlings DJ, Scharenberg AM,Jerome KR (2011). Successful targeting and disruption of anintegrated reporter lentivirus using the engineered homing endonuclease Y2 I-AniI. PLoS One 6:e16825
  • Bell TG, Kramvis A (2016) The study of hepatitis B virus usingbioinformatics. Bioinformatics. In: Abdurakhmonov IY (ed) Bioinformatics.
  • Casciano JC, Bouchard MJ (2018). Hepatitis B virus X proteinmodulates cytosolic Ca(2+) signaling in primary human hepatocytes. Virus Res 246:23-27
  • Cho SW, Kim S, Kim Y, Kweon J, Kim HS, Bae S, Kim JS (2014).Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res 24:132-141
  • Cradick TJ, Keck K, Bradshaw S, Jamieson AC, McCaffrey AP(2010). Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther 18:947-954
  • Doerflinger M, Forsyth W, Ebert G, Pellegrini M, Herold MJ(2017). CRISPR/Cas9-The ultimate weapon to battle infectious diseases? Cell Microbiol 19:
  • Dong C, Qu L, Wang H, Wei L, Dong Y, Xiong S (2015).Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nucleaseefficiently inhibits viral replication. Antiviral Res 118:110-117
  • Doudna JA, Charpentier E (2014). Genome editing. The newfrontier of genome engineering with CRISPR-Cas9. Science 346:1258096
  • Gish RG, Given BD, Lai CL, Locarnini SA, Lau JY, Lewis DL,Schluep T (2015). Chronic hepatitis B: Virology, natural history,current management and a glimpse at future opportunities. Antiviral Res 121:47-58
  • Glebe D (2007). Viral and cellular determinants involved in hepadnaviral entry. World J Gastroenterol 13:22-38
  • He Z, Proudfoot C, Whitelaw CB, Lillico SG (2016). Comparisonof CRISPR/Cas9 and TALENs on editing an integrated EGFP gene in the genome of HEK293FT cells. Springerplus 5:814
  • Hongthanakorn C, Chotiyaputta W, Oberhelman K, Fontana RJ,Marrero JA, Licari T, Lok AS (2011). Virological breakthroughand resistance in patients with chronic hepatitis B receivingnucleos(t)ide analogues in clinical practice. Hepatology 53:1854-Hsu PD, Lander ES, Zhang F (2014). Development andapplications of CRISPR-Cas9 for genome engineering. Cell 157:1262-1278
  • Lu, Daru (2018). New applications of CRISPR/Cas9 system on mutant DNA detection Gene 641:55-62
  • Karayiannis P (2017). Hepatitis B virus: virology, molecularbiology, life cycle and intrahepatic spread. Hepatol Int 11:500-Karimova M, Beschorner N, Dammermann W, Chemnitz J,Indenbirken D, Bockmann JH, Grundhoff A, Luth S, Buchholz F,Schulze zur Wiesch J, Hauber J (2015). CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X. Sci Rep 5:13734
  • Kennedy EM, Bassit LC, Mueller H, Kornepati AVR, Bogerd HP,Nie T, Chatterjee P, Javanbakht H, Schinazi RF, Cullen BR(2015). Suppression of hepatitis B virus DNA accumulation inchronically infected cells using a bacterial CRISPR/Cas RNA- guided DNA endonuclease. Virology 476:196-205
  • Kennedy EM, Kornepati AV, Cullen BR (2015). Targetinghepatitis B virus cccDNA using CRISPR/Cas9. Antiviral Res 123:188-192
  • Kim H, Kim JS (2014). A guide to genome engineering with programmable nucleases. Nat Rev Genet 15:321-334
  • Kitamura K, Que L, Shimadu M, Koura M, Ishihara Y, Wakae K,Nakamura T, Watashi K, Wakita T, Muramatsu M (2018). Flapendonuclease 1 is involved in cccDNA formation in the hepatitis B virus. PLoS Pathog 14:e1007124
  • Komatsu H (2014). Hepatitis B virus: where do we stand andwhat is the next step for eradication? World J GastroenterolKostyushev D, Brezgin S, Kostyusheva A, Zarifyan D, Goptar I,Chulanov V (2019). Orthologous CRISPR/Cas9 systems forspecific and efficient degradation of covalently closed circular DNA of hepatitis B virus. Cell Mol Life Sci 76:1779-1794
  • Kostyushev D, Kostyusheva A, Brezgin S, Zarifyan D, Utkina A,Goptar I, Chulanov V (2019). Suppressing the NHEJ pathway byDNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9. Sci Rep 9:1847
  • Kostyusheva A, Kostyushev D, Brezgin S, Volchkova E, &Chulanov V (2018). Clinical implications of hepatitis B virusRNA and covalently closed circular DNA in monitoring patientswith chronic hepatitis B today with a gaze into the future: the field is unprepared for a sterilizing cure. Genes 9:483
  • Kostyusheva AP, Kostyushev DS, Brezgin SA, Zarifyan DN,Volchkova EV, Chulanov VP (2019). Small Molecular Inhibitorsof DNA Double Strand Break Repair Pathways Increase theANTI-HBV Activity of CRISPR/Cas9. Molecular Biology 53:274-Kurihara T, Fukuhara T, Ono C, Yamamoto S, Uemura K,Okamoto T, Sugiyama M, Motooka D, Nakamura S, Ikawa M,Mizokami M, Maehara Y, Matsuura Y (2017). Suppression ofHBV replication by the expression of nickase- and nuclease dead-Cas9. Sci Rep 7:6122
  • Lamontagne RJ, Casciano JC, Bouchard MJ (2018). A broadinvestigation of the HBV-mediated changes to primaryhepatocyte physiology reveals HBV significantly alters metabolic pathways. Metabolism 83:50-59
  • Li H, Sheng C, Liu H, Liu G, Du X, Du J, Zhan L, Li P, Yang C,Qi L, Wang J, Yang X, Jia L, Xie J, Wang L, Hao R, Xu D, Tong Y,Zhou Y, Zhou J, Sun Y, Li Q, Qiu S, Song H (2016). An EffectiveMolecular Target Site in Hepatitis B Virus S Gene for Cas9Cleavage and Mutational Inactivation. Int J Biol Sci 12:1104-1113Li H, Sheng C, Liu H, Wang S, Zhao J, Yang L, Jia L, Li P, WangL, Xie J, Xu D, Sun Y, Qiu S, Song H (2018). Inhibition of HBVExpression in HBV Transgenic Mice Using AAV-Delivered CRISPR-SaCas9. Front Immunol 9:2080
  • Lin CL, Yang HC, Kao JH (2016). Hepatitis B virus: new therapeutic perspectives. Liver Int 36 Suppl 1:85-92
  • Lin SR, Yang HC, Kuo YT, Liu CJ, Yang TY, Sung KC, Lin YY,Wang HY, Wang CC, Shen YC, Wu FY, Kao JH, Chen DS, ChenPJ (2014). The CRISPR/Cas9 System Facilitates Clearance of theIntrahepatic HBV Templates In Vivo. Mol Ther Nucleic Acids 3:e186
  • Liu K-CL, BS; Gao, An-Ding; Ma, Hong-Yu; Zhoa, Meng; Zhang,Rui; Yan, Hui-Hui; Yi, Xun-Fei; Lin, Si-Jie; Que, Jian-Wen; Lan,Xiao-Peng (2014). Integrase-Deficient Lentivirus: Opportunitiesand Challenges for Human Gene Therapy. Current Gene Theraphy 14:352-364
  • Liu X, Hao R, Chen S, Guo D, Chen Y (2015). Inhibition ofhepatitis B virus by the CRISPR/Cas9 system via targeting theconserved regions of the viral genome. J Gen Virol 96:2252-2261Liu Y, Zhao M, Gong M, Xu Y, Xie C, Deng H, Li X, Wu H,Wang Z (2018). Inhibition of hepatitis B virus replication viaHBV DNA cleavage by Cas9 from Staphylococcus aureus. Antiviral Res 152:58-67
  • Makarova KS, Koonin EV (2015) Annotation and Classification of CRISPR-Cas Systems. In: Crispr. pp 47-75
  • Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, NorvilleJE, Church GM (2013). RNA-Guided Human Genome Engineering via Cas9. Science 339:823-826
  • Memi F, Ntokou A, Papangeli I (2018). CRISPR/Cas9 gene-editing: Research technologies, clinical applications and ethical considerations. In Seminars in perinatology 42:487-500
  • Moyo B, Bloom K, Scott T, Ely A, Arbuthnot P (2018). Advanceswith using CRISPR/Cas-mediated gene editing to treat infectionswith hepatitis B virus and hepatitis C virus. Virus Res 244:311-Ohno M, Otsuka M, Kishikawa T, Yoshikawa T, Takata A, KoikeK (2015). Novel therapeutic approaches for hepatitis B viruscovalently closed circular DNA. World J Gastroenterol 21:7084-Pattanayak V, Lin S, Guilinger JP, Ma E, Doudna JA, Liu DR(2013). High-throughput profiling of off-target DNA cleavagereveals RNA-programmed Cas9 nuclease specificity. Nat Biotechnol 31:839-843
  • Peng C, Lu M, Yang D (2015). CRISPR/Cas9-based tools fortargeted genome editing and replication control of HBV. Virol Sin 30:317-325
  • Peng Z, Ouyang T, Pang D, Ma T, Chen X, Guo N, Chen F, YuanL, Ouyang H, Ren L (2016). Pseudorabies virus can escape from CRISPR-Cas9-mediated inhibition. Virus Res 223:197-205
  • Pickar-Oliver A, Gersbach CA (2019). The next generation ofCRISPR-Cas technologies and applications. Nat Rev Mol Cell Biol 20:490-507
  • (2014). CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell 159:440-455
  • Pollicino T, Cacciola I, Saffioti F, Raimondo G (2014). HepatitisB virus PreS/S gene variants: pathobiology and clinical implications. J Hepatol 61:408-417
  • Ramanan V, Shlomai A, Cox DB, Schwartz RE, Michailidis E,Bhatta A, Scott DA, Zhang F, Rice CM, Bhatia SN (2015).CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci Rep 5:10833
  • Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ,Zetsche B, Shalem O, Wu X, Makarova KS, Koonin EV, SharpPA, Zhang F (2015). In vivo genome editing using Staphylococcus aureus Cas9. Nature 520:186-191
  • Sakuma T, Masaki K, Abe-Chayama H, Mochida K, YamamotoT, Chayama K (2016). Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus. Genes Cells 21:1253-1262
  • Salsman J, Dellaire G (2017). Precision genome editing in the CRISPR era. Biochem Cell Biol 95:187-201
  • Schiffer JT, Swan DA, Stone D, Jerome KR (2013). Predictors ofhepatitis B cure using gene therapy to deliver DNA cleavageenzymes: a mathematical modeling approach. PLoS Comput Biol 9:e1003131
  • Schiwon M, Ehrke-Schulz E, Oswald A, Bergmann T, Michler T,Protzer U, Ehrhardt A (2018). One-Vector System forMultiplexed CRISPR/Cas9 against Hepatitis B Virus cccDNAUtilizing High-Capacity Adenoviral Vectors. Mol Ther Nucleic Acids 12:242-253
  • Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M,Gate RE, Haliburton GE, Ye CJ, Bluestone JA, Doudna JA,Marson A (2015). Generation of knock-in primary human T cellsusing Cas9 ribonucleoproteins. Proc Natl Acad Sci U S AScott T, Moyo B, Nicholson S, Maepa MB, Watashi K, Ely A,Weinberg MS, Arbuthnot P (2017). ssAAVs containing cassettesencoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells. Sci Rep 7:7401
  • Seeger C, Sohn JA (2014). Targeting Hepatitis B Virus With CRISPR/Cas9. Mol Ther Nucleic Acids 3:e216
  • Seeger C, Sohn JA (2016). Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA. Mol Ther 24:1258-1266
  • Shen B, Zhang W, Zhang J, Zhou J, Wang J, Chen L, Wang L,Hodgkins A, Iyer V, Huang X, Skarnes WC (2014). Efficientgenome modification by CRISPR-Cas9 nickase with minimal off- target effects. Nat Methods 11:399-402
  • Slagle BL, Bouchard MJ (2018). Role of HBx in hepatitis B viruspersistence and its therapeutic implications. Curr Opin VirolSong J, Zhang X, Ge Q, Yuan C, Chu L, Liang HF, Liao Z, Liu Q,Zhang Z, Zhang B (2018). CRISPR/Cas9-mediated knockout ofHBsAg inhibits proliferation and tumorigenicity of HBV-positive hepatocellular carcinoma cells. J Cell Biochem 119:8419-Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, SprattSK, Surosky RT, Giedlin MA, Nichol G, Holmes MC, GregoryPD, Ando DG, Kalos M, Collman RG, Binder-Scholl G, Plesa G,Hwang WT, Levine BL, June CH (2014). Gene editing of CCR5in autologous CD4 T cells of persons infected with HIV. N Engl J Med 370:901-910
  • Trono D, Van Lint C, Rouzioux C, Verdin E, Barre-Sinoussi F,Chun TW, Chomont N (2010). HIV persistence and the prospectof long-term drug-free remissions for HIV-infected individuals. Science 329:174-180
  • Tsai KN, Kuo CF, Ou JJ (2018). Mechanisms of Hepatitis B Virus Persistence. Trends Microbiol 26:33-42
  • Wang G, Zhao N, Berkhout B, Das AT (2016). CRISPR-Cas9 CanInhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape. Mol Ther 24:522-526
  • Wang J, Chen R, Zhang R, Ding S, Zhang T, Yuan Q, Guan G,Chen X, Zhang T, Zhuang H, Nunes F, Block T, Liu S, Duan Z,Xia N, Xu Z, Lu F (2017). The gRNA-miRNA-gRNA TernaryCassette Combining CRISPR/Cas9 with RNAi ApproachStrongly Inhibits Hepatitis B Virus Replication. TheranosticsWang J, Xu ZW, Liu S, Zhang RY, Ding SL, Xie XM, Long L,Chen XM, Zhuang H, Lu FM (2015). Dual gRNAs guidedCRISPR/Cas9 system inhibits hepatitis B virus replication. World J Gastroenterol 21:9554-9565
  • Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K,Petersen J, Lau G, Trepo C, Marcellin P, Goodman Z, DelaneyWEt, Xiong S, Brosgart CL, Chen SS, Gibbs CS, Zoulim F (2004).Persistence of cccDNA during the natural history of chronichepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126:1750-1758
  • Wooddell CI, Rozema DB, Hossbach M, John M, Hamilton HL,Chu Q, Hegge JO, Klein JJ, Wakefield DH, Oropeza CE, DeckertJ, Roehl I, Jahn-Hofmann K, Hadwiger P, Vornlocher HP,McLachlan A, Lewis DL (2013). Hepatocyte-targeted RNAitherapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther 21:973-985
  • Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P,Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M,Fischer C, Currie G, Brosgart C, Petersen J (2006). Peginterferonalpha-2b plus adefovir induce strong cccDNA decline andHBsAg reduction in patients with chronic hepatitis B. Hepatology 44:675-684
  • Xiao-Jie L, Hui-Ying X, Zun-Ping K, Jin-Lian C, Li-Juan J (2015).CRISPR-Cas9: a new and promising player in gene therapy. J Med Genet 52:289-296
  • Yang HC, Chen PJ (2018). The potential and challenges ofCRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA. Virus Res 244:304-310
  • Yin H, Song CQ, Dorkin JR, Zhu LJ, Li Y, Wu Q, Park A, Yang J,Suresh S, Bizhanova A, Gupta A, Bolukbasi MF, Walsh S,Bogorad RL, Gao G, Weng Z, Dong Y, Koteliansky V, Wolfe SA,Langer R, Xue W, Anderson DG (2016). Therapeutic genomeediting by combined viral and non-viral delivery of CRISPR system components in vivo. Nat Biotechnol 34:328-333
  • Zhang F, Wen Y, Guo X (2014). CRISPR/Cas9 for genomeediting: progress, implications and challenges. Hum Mol Genet 23:R40-46
  • Zhen S, Hua L, Liu YH, Gao LC, Fu J, Wan DY, Dong LH, SongHF, Gao X (2015). Harnessing the clustered regularly interspacedshort palindromic repeat (CRISPR)/CRISPR-associated Cas9system to disrupt the hepatitis B virus. Gene Ther 22:404-412
  • Zheng Q, Bai L, Zheng S, Liu M, Zhang J, Wang T, Xu Z, ChenY, Li J, Duan Z (2017). Efficient inhibition of duck hepatitis B
  • Zhu W, Xie K, Xu Y, Wang L, Chen K, Zhang L, Fang J (2016).CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse. Virus Res 217:125-132
  • Zoulim F (2011). Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int 31 Suppl 1:111-116
MAKALE İSTATİSTİKLERİ

                                                                                                                                                                                                        

                                                                                                                                                                                                        

                                                                                                                                                                                                        
                                                                                                                                                                                                        
                                                                                                                                                                                                        

                                                                                                                                                                                                        

                                                                                                                                                                                                        



                                                                                                                                                                                                        

                                                                                                                                                                                                        
 
                                                                                                                                                                                                        
                      
                                                                                                                                                                                                        

                                                                                                                                                                                                        

                                                                                                                                                                                                        
LINKS

                                                                                                                                                                                                        
    
                                                                                                                                                                                                        
  • 
                                                                                                                                                                                                        
    
                                                                                                                                                                                                        
    

                                                                                                                                                                                                        
     Last issue
    
                                                                                                                                                                                                        
    
                                                                                                                                                                                                        
    • 
                                                                                                                                                                                                        
  • 
                                                                                                                                                                                                        
    
                                                                                                                                                                                                        
    
                                                                                                                                                                                                        
         Previous issues
    
                                                                                                                                                                                                        
    
                                                                                                                                                                                                        
    • 
                                                                                                                                                                                                        
  • 
                                                                                                                                                                                                        
    
                                                                                                                                                                                                        
    
                                                                                                                                                                                                        
    Article Statistics
    
                                                                                                                                                                                                        
    
                                                                                                                                                                                                        
    • 

                                                                                                                                                                                                        
                                                                                                                                                                                                        




                                                                                                                                                                                                        


                                                                                                                                                                                                        

                                                                                                                                                                                                        



                                                                                                                                                                                                        

                                                                                                                                                                                                        

                                                                                                                                                                                                        
Share